Literature DB >> 9770330

Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis.

S Kuiper1, L A Joosten, A M Bendele, C K Edwards, O J Arntz, M M Helsen, F A Van de Loo, W B Van den Berg.   

Abstract

In this study two different aspects of tumour necrosis factor alpha (TNF-alpha) and interleukin 1 (IL-1) in locally induced murine streptococcal cell wall arthritis (SCW) were investigated. First, the kinetics and interdependence of TNF-alpha and IL-1 release; and second; their involvement in inflammation and cartilage destruction. Kinetic studies showed that the TNF-alpha peak level preceded the IL-1 peak level. However, in vivo neutralization of TNF-alpha did not result in decreased IL-1 bioactivity or immunoreactivity, suggesting that there is no dominant TNF-alpha-dependent IL-1 release in this model. Inflammation was studied by measuring knee joint swelling and inflammatory cell influx. Impact on cartilage was studied by measuring chondrocyte proteoglycan synthesis and cartilage proteoglycan depletion. The role of TNF-alpha in these phenomena was investigated using anti-TNF-alpha antibodies and tumour necrosis factor binding protein (TNFbp). Similarly, the role of IL-1 was studied using anti-IL-1 antibodies or IL-1 receptor antagonist (IL-1Ra). Anti-TNF-alpha treatment significantly reduced joint swelling, whereas this effect was not found by using anti-IL-1 or IL-1Ra. In contrast, neutralization of IL-1, but not TNF-alpha, resulted in a significant decrease of chondrocyte proteoglycan synthesis inhibition. Moreover, histology revealed that anti-IL-1 treatment reduced cartilage proteoglycan depletion and inflammatory cell influx. Combined anti-TNF-alpha/anti-IL-1 treatment significantly suppressed both inflammation and cartilage damage. However, the impact on these separate parameters did not exceed the effects of either anti-TNF-alpha or anti-TNF-1. It can be concluded that both TNF-alpha and IL-1 exert specific activities in SCW arthritis. The involvement of TNF-alpha in this model is limited to joint swelling, whereas IL-1 plays a dominant role in cartilage destruction and inflammatory cell influx. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770330     DOI: 10.1006/cyto.1998.0372

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  32 in total

Review 1.  Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update.

Authors:  M W Davis; U Feige; A M Bendele; S W Martin; C K Edwards
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Gene targeting: roadmap to future therapies.

Authors:  Lars C Huber; Thomas Pap; Ulf Müller-Ladner; Renate E Gay; Steffen Gay
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 4.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

5.  Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra.

Authors:  L A Joosten; M M Helsen; W B van Den Berg
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

6.  Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.

Authors:  L Tissi; M Puliti; R Barluzzi; G Orefici; C von Hunolstein; F Bistoni
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction.

Authors:  Leo A B Joosten; Ruben L Smeets; Marije I Koenders; Liduine A M van den Bersselaar; Monique M A Helsen; Birgitte Oppers-Walgreen; Erik Lubberts; Yoichiro Iwakura; Fons A J van de Loo; Wim B van den Berg
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.

Authors:  Giulio Cavalli; Marije Koenders; Vassili Kalabokis; Jihye Kim; Aik Choon Tan; Cecilia Garlanda; Alberto Mantovani; Lorenzo Dagna; Leo A B Joosten; Charles A Dinarello
Journal:  Rheumatology (Oxford)       Date:  2016-08-26       Impact factor: 7.580

Review 9.  The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis.

Authors:  Gary S Firestein
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment.

Authors:  I Rioja; K A Bush; J B Buckton; M C Dickson; P F Life
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.